NCT01331421已完成不适用
A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- bioequivalence determined by statistical comparison Cmax
研究概览
简要总结
The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fasted conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs.
- •History of allergic or adverse response to exemestane or any comparable or similar product.
结局指标
主要结局
bioequivalence determined by statistical comparison Cmax
时间窗: 21 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsBreast CancerNCT01331447Roxane Laboratories12
已完成
不适用
Bioequivalency Study of Exemestane 25 mg Tablet Under Fed ConditionsBreast CancerNCT01331434Roxane Laboratories47
撤回
1 期
Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy SubjectsHealthyNCT01760980Actavis Inc.
已完成
1 期
Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mgHealthyNCT00648791Mylan Pharmaceuticals Inc29
已完成
早期 1 期
Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted ConditionsAsthmaNCT01659931Roxane Laboratories34